全文获取类型
收费全文 | 17480篇 |
免费 | 1128篇 |
国内免费 | 140篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 458篇 |
妇产科学 | 177篇 |
基础医学 | 1073篇 |
口腔科学 | 256篇 |
临床医学 | 3833篇 |
内科学 | 1852篇 |
皮肤病学 | 134篇 |
神经病学 | 568篇 |
特种医学 | 312篇 |
外科学 | 2170篇 |
综合类 | 2324篇 |
预防医学 | 2989篇 |
眼科学 | 114篇 |
药学 | 1268篇 |
12篇 | |
中国医学 | 490篇 |
肿瘤学 | 546篇 |
出版年
2024年 | 33篇 |
2023年 | 466篇 |
2022年 | 895篇 |
2021年 | 1069篇 |
2020年 | 871篇 |
2019年 | 1130篇 |
2018年 | 1013篇 |
2017年 | 683篇 |
2016年 | 579篇 |
2015年 | 613篇 |
2014年 | 1456篇 |
2013年 | 1392篇 |
2012年 | 1169篇 |
2011年 | 1319篇 |
2010年 | 1006篇 |
2009年 | 772篇 |
2008年 | 586篇 |
2007年 | 559篇 |
2006年 | 441篇 |
2005年 | 324篇 |
2004年 | 286篇 |
2003年 | 272篇 |
2002年 | 219篇 |
2001年 | 175篇 |
2000年 | 147篇 |
1999年 | 145篇 |
1998年 | 106篇 |
1997年 | 82篇 |
1996年 | 77篇 |
1995年 | 59篇 |
1994年 | 61篇 |
1993年 | 51篇 |
1992年 | 55篇 |
1991年 | 31篇 |
1990年 | 34篇 |
1989年 | 30篇 |
1988年 | 40篇 |
1986年 | 25篇 |
1985年 | 55篇 |
1984年 | 57篇 |
1983年 | 30篇 |
1982年 | 36篇 |
1981年 | 33篇 |
1980年 | 33篇 |
1979年 | 23篇 |
1977年 | 21篇 |
1974年 | 25篇 |
1973年 | 21篇 |
1972年 | 28篇 |
1971年 | 20篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
IntroductionHip displacement is common in cerebral palsy (CP) and is related to the severity of neurological and functional impairment. It is a silent, but progressive disease, and can result in significant morbidity and decreased quality of life, if left untreated. The pathophysiology of hip displacement in CP is a combination of hip flexor-adductor muscle spasticity, abductor muscle weakness, and delayed weight-bearing, resulting in proximal femoral deformities and progressive acetabular dysplasia. Due to a lack of symptoms in the early stages of hip displacement, the diagnosis is easily missed. Awareness of this condition and regular surveillance by clinical examination and serial radiographs of the hips are the key to early diagnosis and treatment.Hip surveillance programmesSeveral population-based studies from around the world have demonstrated that universal hip surveillance in children with CP allows early detection of hip displacement and appropriate early intervention, with a resultant decrease in painful dislocations. Global hip surveillance models are based upon the patients’ age, functional level determined by the Gross Motor Function Classification system (GMFCS), gait classification, standardized clinical exam, and radiographic indices such as the migration percentage (MP), as critical indicators of progressive hip displacement.ConclusionDespite 25 years of evidence showing the efficacy of established hip surveillance programmes, there is poor awareness among healthcare professionals in India about the importance of regular hip surveillance in children with CP. There is a need for professional organizations to develop evidence-based guidelines for hip surveillance which are relevant to the Indian context. 相似文献
2.
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
4.
《Research in social & administrative pharmacy》2022,18(9):3694-3698
In this paper, we argue that understanding and addressing the problem of poor-quality medical products requires a more interdisciplinary approach than has been evident to date. While prospective studies based on rigorous standardized methodologies are the gold standard for measuring the prevalence of poor-quality medical products and understanding their distribution nationally and internationally, they should be complemented by social science research to unpack the complex set of social, economic, and governance factors that underlie these patterns. In the following sections, we discuss specific examples of prospective quality surveys and of social science studies, highlighting the value of cross-sector partnerships in driving high-quality, policy-relevant research in this area. 相似文献
5.
6.
7.
8.
《Neuro-Chirurgie》2022,68(3):262-266
BackgroundThe prognosis for patients with recurrent glioblastoma (GBM) is dismal, and the question of repeat surgery at time of recurrence is common. Re-operation in the management of these patients remains controversial, as there is no randomized evidence of benefit. An all-inclusive pragmatic care trial is needed to evaluate the role of repeat resection.Methods3rGBM is a multicenter, pragmatic, prospective, parallel-group randomized care trial, with 1:1 allocation to repeat resection or standard care with no repeat resection. To test the hypothesis that repeat resection can improve overall survival by at least 3 months (from 6 to 9 months), 250 adult patients with prior resection of pathology-proven glioblastoma for whom the attending surgeon believes repeat resection may improve quality survival will be enrolled. A surrogate measure of quality of life, the number of days outside of hospital/nursing/palliative care facility, will also be compared. Centers are invited to participate without financial compensation and without contracts. Clinicians may apply to local authorities to approve an investigator-led in-house trial, using a common protocol, web-based randomization platform, and simple standardized case report forms.DiscussionThe 3rGBM trial is a modern transparent care research framework with no additional risks, tests, or visits other than what patients would encounter in normal care. The burden of proof remains on repeat surgical management of recurrent GBM, because this management has yet to be shown beneficial. The trial is designed to help patients and surgeons manage the uncertainty regarding optimal care.Clinical Trial Registrationhttp://www.clinicaltrials.gov. Unique identifier: NCT04838782. 相似文献
9.
10.